AICAR
An AMPK-activating nucleoside analog with niche clinical research history; not an approved therapeutic, and prohibited in sport.
What it is
AICAR is a nucleoside analog that activates AMPK, the cell's energy-stress sensor — which earned it the 'exercise in a pill' label after famous rodent experiments improved endurance without training. It is not a peptide, and it is not an approved drug.
It carries one of the more colorful anti-doping histories in this library: WADA banned it explicitly after evidence of use in professional cycling. Its human research history is real but narrow — older clinical work in cardiac settings — and none of it supports the athletic or fat-loss uses it's sold for.
What researchers have actually studied it for
Cardiac ischemia protection in older clinical research; endurance and metabolism in rodent studies that made it an anti-doping target.
How it works
Inside cells AICAR converts to ZMP, an AMP mimic that switches on AMPK — the master sensor that tells a cell it's low on energy. Downstream: increased glucose uptake and fat oxidation, the same program exercise activates, which is precisely why both athletes and regulators noticed it.
The molecule itself
A nucleoside analog — ribose plus an imidazole carboxamide — that cells phosphorylate into ZMP, an AMP mimic. ZMP flips AMPK, the energy-stress master switch, without energy actually being low: chemically informing the cell of a workout that didn't happen.
Where it came from
Studied since the 1980s–90s in cardiology (ischemia-reperfusion protection during bypass surgery), AICAR became famous in 2008 when rodent studies showed endurance gains without exercise. WADA added it to the prohibited list, cycling scandals referenced it, and the gray market has sold it ever since.
The timeline
1980s–90s
Cardiology studies IV AICAR around ischemia and bypass surgery.
2008
The famous rodent endurance study lands; 'exercise pill' era begins.
2009
WADA adds it to the prohibited list.
2010s
Cycling-scandal notoriety; gray-market persistence.
What the research record actually contains
- Older human clinical research in cardiac ischemia settings — a different question entirely.
- Rodent endurance and metabolic studies behind the 'exercise mimetic' reputation.
- No controlled human trials for performance, fat loss or longevity.
What could change this assessment
AMPK activation remains a major pharma target — via characterized drugs like metformin and successors, not AICAR. Its future is as anti-doping chemistry's reference compound.
What's known about risks
Its clinical-era studies involved monitored IV use in surgical patients — nothing like gray-market self-injection. AMPK activation is powerful, systemic and unstudied for chronic self-use; lactic-acid and uric-acid effects appear even in the older literature.
Where it stands legally
Not an approved therapeutic; research-chemical channel; explicitly prohibited by WADA.
Worth asking a licensed provider
- 1.Is there any human evidence for the outcome I'm chasing, or only the 2008 mouse work?
- 2.What would chronic AMPK activation do to my particular metabolic picture?
- 3.Am I tested in any sport — and do I understand this is a named banned substance?
Common claims, corrected
“It gave mice fitness, so it builds human endurance.”
Reality: Untrained mice gained capacity in one landmark study; human performance data doesn't exist, and WADA's ban reflects principle and precedent, not proven human effect.
“Its old surgical trials make it safe for gym use.”
Reality: Monitored IV use in cardiac patients is a different universe from chronic unsupervised self-dosing; the old data doesn't transfer.
AICAR FAQ
Is AICAR really 'exercise in a pill'?
That framing comes from rodent studies where untrained mice gained endurance. Human performance evidence doesn't exist, and WADA banned it on principle and practice alike.
Is AICAR banned in sports?
Yes — explicitly listed by WADA as a metabolic modulator, with real detection methods and real sanctions behind it.
Is AICAR a peptide?
No — it's a nucleoside analog. It lives in peptide catalogs for marketing reasons, not chemical ones.
Why was AICAR in cycling scandals?
Its exercise-mimetic reputation plus detectability challenges made it an early 'undetectable doping' story; testing caught up, sanctions followed.
Is metformin the legitimate version of this idea?
Loosely — metformin engages AMPK among other mechanisms, with decades of human outcome data. It's what the AICAR hypothesis looks like after real development.